Page 4 - Hematologic Malignancies Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights News provided by Share this article - Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments - On track to report clinical biomarker and safety data in breast cancer in 2021 - Strong financial foundation with approximately $50 million in cash on hand and cash runway to H2 2022 - Management hosting conference call and webcast today at 8:30 am ET SAN DIEGO and CALGARY, AB, March 5, 2021 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC...

Reducing Infectious Diarrhea in Organ Transplant and Leukemia Patients by Pooja Shete on  December 10, 2020 at 1:00 PM The most common form of infectious diarrhea in hospitalized patients is caused by bacteria Clostridium difficile. Clostridium difficile infection (CDI) results in inflammation of the colon. The most vulnerable population to develop CDI are those patients undergoing blood and bone marrow transplant (BMT) due to their prolonged hospitalization and previous exposure to antimicrobials. The members of the Hematologic Malignancies Program at Rutgers Cancer Instit...